Optimised coding sequence and promoter
An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
1. An isolated nucleic acid molecule comprising a functional FVIII coding nucleotide sequence having at least 80% homology to the nucleotide sequence of SEQ ID NO: 5 that is operably linked to a liver specific promoter comprising a nucleotide sequence having at least 95% identity to the nucleotide sequence of SEQ ID NO: 3, and wherein in respect to the amino acid sequence encoded by SEQ ID NO: 5 any amino acid changes encoded by the isolated nucleic acid molecule is in the portion of the amino acid sequence which replaced the B domain of the FVIII protein.
2. The nucleic acid molecule of claim 1 , wherein the functional FVIII coding nucleotide sequence has at least 85% homology to the nucleotide sequence of SEQ ID NO: 5.
3. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 80% homology to the nucleotide sequence of SEQ ID NO: 5, and which encodes a functional FVIII protein comprising the sequence of SEQ ID NO: 2 or SEQ ID NO: 21 having between 0 and 10 amino acid changes that are in the portion of the amino acid sequence that replaced the B domain of the FVIII protein.
4. The nucleic acid molecule of claim 3 , which encodes for a protein comprising the sequence of SEQ ID NO: 2 or SEQ ID NO: 21.
5. An isolated nucleic acid molecule comprising a nucleotide sequence having 98% homology to the nucleotide sequence of SEQ ID NO: 5.
6. A vector comprising the nucleic acid molecule of claim 1 .
7. A host cell comprising the nucleic acid molecule of claim 1 or the vector of claim 6 .
8. A method of treating haemophilia comprising administering the vector according to claim 6 to a patient suffering from haemophilia.
9. A method for delivery of a nucleotide sequence encoding a functional factor VIII to a subject, which method comprises administering to the said subject the nucleic acid molecule according to claim 1 .
10. A liver specific promoter comprising a nucleotide sequence having at least 95% homology to the nucleotide sequence of SEQ ID NO: 3 and is less than 350 base pairs in length.
11. A vector comprising the promoter according to claim 10 .
12. A host cell comprising the promoter of claim 10 or the vector of claim 11 .
13. A vector comprising the nucleic acid molecule of claim 3 .
14. A host cell comprising the nucleic acid molecule of claim 3 .
15. A host cell comprising the vector of claim 13 .
16. A vector comprising the nucleic acid molecule of claim 5 .
17. A host cell comprising the nucleic acid molecule of claim 5 .
18. A host cell comprising the vector of claim 16 .
19. A method for delivery of a nucleotide sequence encoding a functional factor VIII to a subject, which method comprises administering to said subject the nucleic acid molecule according to claim 3 .
20. A method for delivery of a nucleotide sequence encoding a functional factor VIII to a subject, which method comprises administering to said subject the nucleic acid molecule according to claim 5 .